RACI NSW Pharmaceutical Sciences Group
Wednesday 24 February at 9.30 am to 11.00 am
Identification of a Novel LNP Delivery System for a COVID-19 Self-amplifying mRNA Vaccine and Enabling Rapid Development using Microfluidics
Presenter, Dr Andrew Geall.
A by-product of the Covid 19 pandemic and urgent worldwide need for a safe and effective vaccine has led the broader community to realise that new medicines do not “just happen”. They are the result of intense research and development of scientists in a combination of many disciplines, involving discovery of active ingredient(s) and a formulation which optimises dose delivery of this active. Also manufacture processes must be efficient and the product is stable for suitable transportation and storage.
The Covid pandemic has intensified the quest for new and innovative vaccines and medicines, of which mRNA technology is a primary example.
The presenter at the webinar is Dr Andrew Geall, CEO RNA Consulting, LLC and Chief Scientific Officer of Precision NanoSystems Inc. (PNI), based in Vancouver, Canada. Andrew and the company are focused on the creation and commercial development of transformative nanoparticle medicines with its partners using their proprietary LNP delivery systems and microfluidic formulation platform, current cutting edge technology.
An abstract of the presentation is:
RNA vaccines are a relatively recent innovation but are at the forefront of the many vaccine technologies providing solutions for the COVID-19 pandemic. This talk shows how PNI have identified a potent LNP delivery system for self-amplifying and how this is now been applied to COVID-19 mRNA vaccines.
In addition, it describes why the NanoAssemblr® GMP System is being used by many companies to provide accelerated clinical and commercial development of COIVID-19 nanomedicines, by reducing the number of engineering batches through seamless transfer of manufacturing process: by eliminating cleaning validation by using a fully disposable single use fluid path; by supporting all stages of clinical development through a modular continuous flow pumping system capable of producing volumes of 200 mL to >100 L at outputs up to 12 L/h; and, by enabling flexibility and redundancy in clinical development plans through simple tech transfer of the GMP System to any global non-GMP and GMP facility.
Andrew has enjoyed a most distinguished career in vaccine technologies in senior positions within therapeutic goods organisations. Further details can be found at https://www.linkedin.com/in/andy-geall-116a9624.
This webinar will be of benefit and interest to all scientists, working in academic and commercial organisations, to enhance knowledge of cutting-edge technologies. It will also be a reminder as to the requirements in bringing and maintaining such technologies under GMP and commercial requirements.
The format of the webinar is that the presenter will give a 30 minute overview, followed by a further Q&A session.
Follow the instructions and which fields to complete as an RACI member or non-member with care. Members with an RACI account should enter their Username and Password and follow subsequent instructions. Non-members will initially need to “Create a new account” and also follow subsequent instructions.
A $10 charge will be made for non- RACI members and free for members.
Registrations close at 5pm, Tuesday 23 February.
For any queries on registration, please contact the NSW Branch coordinator, Claire Jung, Tuesday to Thursday, email email@example.com or Mrs Pam Chantrell, Qld Branch coordinator, phone 0499 550 306.
Please note that this webinar has been at the initiation of instrument suppliers, ATA Scientific through Mr Peter Davis, who has facilitated identification of the presenter and topic to the Pharm Group and is enlarging this webinar’s outreach. The ATA Scientific website is www.atascientific.com.au and Peter can be contacted at firstname.lastname@example.org.